drugset / Trial / NCT03105375

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of X842 in Human: A Single/Multiple Ascending Dose Study

NCT03105375

Phase 0 Completed 39 enrolled Cinclus Pharma Holding AB
Non-randomizedSequentialOpen-labelBasic science

Summary

The purpose of this study is to assess and analyze the safety, tolerability and PK/PD data following single ascending and multiple ascending doses of X842 in healthy subjects.

Timeline

Start
2017-02-21
Primary completion
2017-10-12
Completion
2017-10-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Linaprazan glurate Small molecule
Comparator Omeprazole Other / unclassified Oral

Indications

No indication recorded.